Literature DB >> 28475405

The codon 72 polymorphism of p53 influences cell fate following nutrient deprivation.

Che-Pei Kung1,2, Qin Liu1, Maureen E Murphy1.   

Abstract

The TP53 gene is distinguished as the most frequently mutated gene in cancer. Unlike most cancer-relevant genes, the TP53 gene is also distinguished by the existence of coding region polymorphisms that alter p53 sequence, and in some cases, also alter p53 function. A common coding region variant at amino acid 72 of p53 encodes either proline (P72) or arginine (R72). P72 is the ancestral variant and is most common in populations near the equator. The frequency of the R72 variant increases in a linear manner with latitude. To date, why the R72 variant arose in humans and was possibly selected for has remained unclear. Here-in we show that this single nucleotide polymorphism (SNP) influences the phosphorylation of p53 and the transactivation of the key p53 target CDKN1A (p21) specifically in response to nutrient deprivation, but not in response to conventional cytotoxic agents. Following activation of the kinase AMPK, R72 cells show increased phosphorylation on serine-15 and increased transactivation of the cyclin-dependent kinase inhibitor CDKN1A (p21) and the metabolic response genes PPARGC1B (PGC-1β) and PRKAB2 (AMPK-β2). This is accompanied by increased growth arrest and decreased apoptosis in R72 cells compared with P72 cells. The combined data fit best with the hypothesis that the R72 polymorphism confers increased cell survival in response to nutrient deprivation. This differential response to nutrient deprivation may explain part of selection for this SNP at northern latitudes, where nutrient deprivation might have been more frequent.

Entities:  

Keywords:  AICAR; CDKN1A (p21); growth arrest; nutrient deprivation; p53

Mesh:

Substances:

Year:  2017        PMID: 28475405      PMCID: PMC5639853          DOI: 10.1080/15384047.2017.1323595

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  28 in total

Review 1.  Polymorphic variants in the p53 pathway.

Authors:  M E Murphy
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

2.  Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia.

Authors:  Hong Shi; Si-jie Tan; Hua Zhong; Wenwei Hu; Arnold Levine; Chun-jie Xiao; Yi Peng; Xue-bin Qi; Wei-hua Shou; Run-lin Z Ma; Yi Li; Bing Su; Xin Lu
Journal:  Am J Hum Genet       Date:  2009-04-02       Impact factor: 11.025

3.  Two polymorphic variants of wild-type p53 differ biochemically and biologically.

Authors:  M Thomas; A Kalita; S Labrecque; D Pim; L Banks; G Matlashewski
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  Codon 72 polymorphism (rs1042522) of TP53 is associated with changes in diastolic blood pressure over time.

Authors:  Erwin Reiling; Valeriya Lyssenko; Jolanda M A Boer; Sandra Imholz; W Monique M Verschuren; Bo Isomaa; Tiinamaija Tuomi; Leif Groop; Martijn E T Dollé
Journal:  Eur J Hum Genet       Date:  2011-12-21       Impact factor: 4.246

5.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Authors:  Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

6.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

Authors:  Gareth L Bond; Kim M Hirshfield; Tomas Kirchhoff; Gabriella Alexe; Elisabeth E Bond; Harlan Robins; Frank Bartel; Helge Taubert; Peter Wuerl; William Hait; Deborah Toppmeyer; Kenneth Offit; Arnold J Levine
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

7.  The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation.

Authors:  Amanda K Frank; Julia I-Ju Leu; Yan Zhou; Karthik Devarajan; Tatiana Nedelko; Andres Klein-Szanto; Monica Hollstein; Maureen E Murphy
Journal:  Mol Cell Biol       Date:  2011-01-18       Impact factor: 4.272

Review 8.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

9.  A functionally significant SNP in TP53 and breast cancer risk in African-American women.

Authors:  Maureen E Murphy; Song Liu; Song Yao; Dezheng Huo; Qin Liu; Sonia C Dolfi; Kim M Hirshfield; Chi-Chen Hong; Qiang Hu; Andrew F Olshan; Temidayo O Ogundiran; Clement Adebamowo; Susan M Domchek; Katherine L Nathanson; Barbara Nemesure; Stefan Ambs; William J Blot; Ye Feng; Esther M John; Leslie Bernstein; Wei Zheng; Jennifer J Hu; Regina G Ziegler; Sarah Nyante; Sue A Ingles; Michael F Press; Sandra L Deming; Jorge L Rodriguez-Gil; Christopher A Haiman; Olufunmilayo I Olopade; Kathryn L Lunetta; Julie R Palmer; Christine B Ambrosone
Journal:  NPJ Breast Cancer       Date:  2017-02-27

10.  Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72.

Authors:  M Reinbold; J-L Luo; T Nedelko; B Jerchow; M E Murphy; C Whibley; Q Wei; M Hollstein
Journal:  Oncogene       Date:  2007-11-12       Impact factor: 9.867

View more
  11 in total

1.  The Codon 72 TP53 Polymorphism Contributes to TSC Tumorigenesis through the Notch-Nodal Axis.

Authors:  Jun-Hung Cho; Bhaumik Patel; Santosh Bonala; Hossein Mansouri; Sasikanth Manne; Surya Kumari Vadrevu; Shanawaz Ghouse; Che-Pei Kung; Maureen E Murphy; Aristotelis Astrinidis; Elizabeth P Henske; David J Kwiatkowski; Maciej M Markiewski; Magdalena Karbowniczek
Journal:  Mol Cancer Res       Date:  2019-05-14       Impact factor: 5.852

2.  Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer.

Authors:  Cristabelle De Souza; Jill Madden; Devin C Koestler; Dennis Minn; Dennis J Montoya; Kay Minn; Alan G Raetz; Zheng Zhu; Wen-Wu Xiao; Neeki Tahmassebi; Harikumara Reddy; Nina Nelson; Anthony N Karnezis; Jeremy Chien
Journal:  J Natl Cancer Inst       Date:  2021-09-04       Impact factor: 13.506

3.  Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α.

Authors:  Keerthana Gnanapradeepan; Thibaut Barnoud; Che-Pei Kung; Subhasree Basu; Michele Tavecchio; Jeremy Scott; Andrea Watters; Qing Chen; Andrew V Kossenkov; Maureen E Murphy
Journal:  Genes Dev       Date:  2018-02-20       Impact factor: 11.361

4.  TP53 codon 72 Polymorphism and bladder cancer risk: a meta-analysis and emphasis on the role of tumor or smoking status.

Authors:  Lei Zhang; Yi Wang; Zhiqiang Qin; Ran Li; Rong Cong; Chengjian Ji; Xianghu Meng; Yamin Wang; Jiadong Xia; Ninghong Song
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

Review 5.  Control of metabolism by p53 - Cancer and beyond.

Authors:  Christiaan F Labuschagne; Fabio Zani; Karen H Vousden
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-06-05       Impact factor: 10.680

6.  Common genetic variants in the TP53 pathway and their impact on cancer.

Authors:  Thibaut Barnoud; Joshua L D Parris; Maureen E Murphy
Journal:  J Mol Cell Biol       Date:  2019-07-19       Impact factor: 6.216

7.  Taking up the reins of power: metabolic functions of p53.

Authors:  Timothy Humpton; Karen H Vousden
Journal:  J Mol Cell Biol       Date:  2019-07-19       Impact factor: 6.216

Review 8.  The p53 Tumor Suppressor in the Control of Metabolism and Ferroptosis.

Authors:  Keerthana Gnanapradeepan; Subhasree Basu; Thibaut Barnoud; Anna Budina-Kolomets; Che-Pei Kung; Maureen E Murphy
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-11       Impact factor: 5.555

Review 9.  p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine.

Authors:  Jelena Krstic; Markus Galhuber; Tim J Schulz; Michael Schupp; Andreas Prokesch
Journal:  Int J Mol Sci       Date:  2018-03-20       Impact factor: 6.208

10.  Tumor cells containing the African-Centric S47 variant of TP53 show increased Warburg metabolism.

Authors:  Thibaut Barnoud; Joshua L D Parris; Maureen E Murphy
Journal:  Oncotarget       Date:  2019-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.